文献速递肿瘤 PET/CT神经核医学

68Ga-DOTA-FAPI-04与18F-FDG PET/MR在鼻咽癌中的头对头前瞻性比较

A head-to-head comparison of 68Ga-DOTA-FAPI-04 and 18F-FDG PET/MR in patients with nasopharyngeal carcinoma: a prospective study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-02-20

但18F-FDG检出阳性淋巴结更多。

要点

  • 68Ga-FAPI与18F-FDG对原发灶检出率均为100%。
  • 68Ga-FAPI改善颅底侵犯(8/8)和颅内侵犯(4/4)的显示。
  • 18F-FDG检出阳性淋巴结更多(100 vs 48)。

核心结论

  • 68Ga-FAPI在描绘原发灶及检出疑似远处转移方面优于18F-FDG,尤其在评估颅底和颅内侵犯时,提示其混合PET/MR有潜力作为鼻咽癌一步式分期模态。
  • 但68Ga-FAPI在淋巴结和远处转移评估中的价值仍需进一步研究。

研究设计与样本

  • 前瞻性纳入确诊鼻咽癌患者,所有患者均在1周内完成头颈部68Ga-FAPI PET/MR和18F-FDG PET/MR。

主要发现

  • 68Ga-FAPI与18F-FDG对原发灶检出率均为100%。
  • 原发灶68Ga-FAPI SUVmax为13.87 ± 5.13,低于18F-FDG的17.73 ± 6.84,但差异无统计学意义(p = 0.078)。
  • 与18F-FDG相比,68Ga-FAPI PET改善了8/8例颅底侵犯和4/4例颅内侵犯的显示。
  • 18F-FDG PET检出阳性淋巴结数目远多于68Ga-FAPI(100 vs 48);48对配对淋巴结的SUVmax在68Ga-FAPI显著低于18F-FDG(8.67 ± 3.88 vs 11.79 ± 6.17,p < 0.001)。

关键数值与推荐

  • 以25%SUVmax(68Ga-FAPI)或20%SUVmax(18F-FDG)作为确定肿瘤体积的阈值时,与MRI高度一致。

临床怎么用

  • 对于鼻咽癌患者,68Ga-FAPI PET/MR可能有助于更清晰显示颅底和颅内侵犯,并可能检出18F-FDG未发现的疑似远处小转移,从而影响分期。
  • 由于68Ga-FAPI检出阳性淋巴结少于18F-FDG,淋巴结评估仍需结合18F-FDG或其他方法,其远处转移评估价值有待进一步研究。

局限性

  • 试验为回顾性注册(NCT04554719,2020年9月8日注册)。
  • 68Ga-FAPI在淋巴结和远处转移评估中的价值需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To conduct a head-to-head comparison of the diagnostic ability of 68Ga-DOTA-FAPI-04 (68Ga-FAPI) and 18F-FDG PET/MR in nasopharyngeal carcinoma (NPC) patients. METHODS: Patients diagnosed with NPC were prospectively enrolled. All patients underwent head-and-neck 68Ga-FAPI PET/MR and 18F-FDG PET/MR within 1 week. Primary tumor, lymph node numbers, and tracer uptake were compared by SUVmax and visual evaluation. The primary tumor volumes derived from 68Ga-FAPI, 18F-FDG PET, and MRI were also compared. RESULTS: Fifteen patients were enrolled from June to August 2020. Both 68Ga-FAPI and 18F-FDG PET had 100% detection rate of the primary tumor. The 68Ga-FAPI SUVmax of primary tumors (13.87 ± 5.13) was lower than that of 18F-FDG (17.73 ± 6.84), but the difference was not significant (p = 0.078). Compared with 18F-FDG, 68Ga-FAPI PET improved the delineation of skull-base invasion in eight out of eight patients and intracranial invasion in four out of four patients. When 25%SUVmax of 68Ga-FAPI or 20%SUVmax of 18F-FDG was utilized as a threshold for determining tumor volume, it was highly consistent with MRI. 18F-FDG PET detected much more positive lymph nodes than 68Ga-FAPI (100 vs 48). The SUVmax of 48 paired lymph nodes was significantly lower on 68Ga-FAPI than 18F-FDG (8.67 ± 3.88 vs 11.79 ± 6.17, p < 0.001). Additionally, 68Ga-FAPI further detected four highly suspected small, distant metastases in three patients. Compared with 18F-FDG, 68Ga-FAPI changed overall staging in six of fifteen patients, with three patients being up-staged, and three down-staged. CONCLUSION: 68Ga-FAPI outperforms 18F-FDG in delineating the primary tumor and detecting suspected distant metastases, particularly in the evaluation of skull-base and intracranial invasion, suggesting 68Ga-FAPI hybrid PET/MR has the potential to serve as a single-step staging modality for patients with NPC. However, its value regarding lymph node and distant metastases evaluation needs further study. TRIAL REGISTRATION: NCT04554719. Registered September 8, 2020 - retrospectively registered, http://clinicaltrails.gov/show/NCT04554719.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Qin C, Liu F, Huang J, et al. A head-to-head comparison of 68Ga-DOTA-FAPI-04 and 18F-FDG PET/MR in patients with nasopharyngeal carcinoma: a prospective study. Eur J Nucl Med Mol Imaging. 2021. PMID: 33609152. doi:10.1007/s00259-021-05255-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。